AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$NTRA

Moshkevich Solomon sold $5.9M of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 18,160 shares of Natera, Inc. (NTRA) at an average of $325.88 ($319.76–$326.89, $5.92M total) across 4 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Sep 4, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

Insider sales are monitored for signals of management confidence; a $5.9M sale by the president is noteworthy but not decisive.

02

Market read

The filing provides fresh data on insider activity, offering a modest trading cue for NTRA.

03

What to watch

Potential tax planning or diversification; the insider retains a sizable stake.

Relevance 5/10Novelty 7/10Timing: post‑filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President of Natera sold 18,160 shares for $5.9M via a 10b5‑1 plan.

Expected impact

Potential modest dip of 1‑2% in the next trading session.

Evidence & confidence

A $5.9M sale by a senior officer is material but not large enough to trigger a sharp move.

Market effects

Sector

Limited; may slightly affect biotech sentiment but no broader sector impact.

Regional

U.S. biotech investors may adjust positions.

Global

Low; isolated to Natera.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    Natera, Inc.

    US‑listed prenatal testing company (ticker NTRA).

  • Individual
    Moshkevich Solomon

    President, Clinical Diagnostics at Natera.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

OCT 9
$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

financialcontent.com1 min
OCT 9
$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.

finance.yahoo.com2 min